{
    "id": 2855,
    "fullName": "NPM1 exon12",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NPM1 exon12 mutations are found in AML with normal karyotype and predominantly result in a frameshift at the C-terminal, with mutation of either or both T288 and/or T290 and five new terminal residues, VSLRK. As these mutations result in the cytoplasmic location of Npm1 protein, they are also called NPM1c+ or NPMc+ (PMID: 15659725, PMID: 16076867) and are transforming in cell culture (PMID: 26884713).",
            "references": [
                {
                    "id": 1523,
                    "pubMedId": 16076867,
                    "title": "Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16076867"
                },
                {
                    "id": 1522,
                    "pubMedId": 15659725,
                    "title": "Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15659725"
                },
                {
                    "id": 15972,
                    "pubMedId": 26884713,
                    "title": "Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884713"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4869,
        "geneSymbol": "NPM1",
        "terms": [
            "NPM1",
            "B23",
            "NPM"
        ]
    },
    "variant": "exon12",
    "createDate": "12/29/2014",
    "updateDate": "03/10/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10911,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ixazomib (MLN9708) and Zolinza (vorinostat) synergistically induced apoptosis in NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia cells in culture (PMID: 26634271).",
            "molecularProfile": {
                "id": 2682,
                "profileName": "NPM1 exon12"
            },
            "therapy": {
                "id": 1360,
                "therapyName": "Ixazomib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8925,
                    "pubMedId": 26634271,
                    "title": "Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26634271"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10910,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Ixazomib (MLN9708) treatment resulted in significantly reduced peripheral blast cells in a NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia (AML) patient, and demonstrated selective toxicity towards NPMc+ AML cell lines in culture (PMID: 26634271).",
            "molecularProfile": {
                "id": 2682,
                "profileName": "NPM1 exon12"
            },
            "therapy": {
                "id": 1359,
                "therapyName": "Ixazomib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8925,
                    "pubMedId": 26634271,
                    "title": "Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26634271"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1561,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, deguelin treatment of an AML cell line harboring NPM1 exon12 mutation resulted in reduced levels of mutant Npm1 protein and induced differentiation of the cells (PMID: 25242579, PMID: 25348016).",
            "molecularProfile": {
                "id": 2682,
                "profileName": "NPM1 exon12"
            },
            "therapy": {
                "id": 1867,
                "therapyName": "Deguelin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1526,
                    "pubMedId": 25242579,
                    "title": "Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25242579"
                },
                {
                    "id": 1527,
                    "pubMedId": 25348016,
                    "title": "Nontoxic-dose of deguelin induce NPMc+ AML cell differentiation by selectively targeting Mt NPM1/SIRT1 instead of HDAC1/3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25348016"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2682,
            "profileName": "NPM1 exon12",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}